Pivotal Advance: Bifidobacteria and Gram-negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease

被引:71
作者
De Palma, G. [1 ]
Cinova, J. [2 ]
Stepankova, R. [2 ]
Tuckova, L. [2 ]
Sanz, Y. [1 ]
机构
[1] Natl Spanish Res Council CSIC, Inst Agrochem & Food Technol IATA, Microbial Ecol & Nutr Grp, Valencia, Spain
[2] Acad Sci Czech Republic, Inst Microbiol, Dept Immunol, Prague, Czech Republic
关键词
gliadins; IFN-gamma; DENDRITIC CELLS; IN-VITRO; T-CELLS; MICROBIOTA; MONOCYTES; STRAINS; GLIADIN; PATHOGENESIS; MODULATION; ACTIVATION;
D O I
10.1189/jlb.0709471
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
CD is a chronic inflammatory disorder of the small intestine that presents in genetically predisposed individuals following gluten consumption. In this study, the effects of Bifidobacterium (Bifidobacterium bifidum IATA-ES2 and Bifidobacterium longum ATCC15707) and Gram-negative bacteria (Bacteroides fragilis DSM2451, Escherichia coli CBL2, and Shigella CBD8 isolated from CD patients), alone and in the presence of CD triggers (gliadins and/or IFN-gamma) on surface marker expression and cytokine production by PBMCs, were determined. These effects were also evaluated in cocultures of PBMCs and Caco-2 cells. The Gram-negative bacteria induced higher secretion of Th1-type proinflammatory cytokines (IL-12 and/or IFN-gamma) than the Bifidobacterium strains. Shigella CBD8 and E. coli CBL2 up-regulated mainly HLA-DR and CD40 expression involved in Th1 activation, and Bifidobacterium strains up-regulated CD83 expression. Specific interactions among the studied bacteria, gliadins, and IFN-gamma, which favored the CD immune features, were also detected. Therefore, intestinal bacteria could be additional factors that regulate the ability of monocytes recruited to the mucosa to respond to gliadins and IFN-gamma in CD patients, influencing the course of the disease. J. Leukoc. Biol. 87: 765-778; 2010.
引用
收藏
页码:765 / 778
页数:14
相关论文
共 32 条
[11]   Supernatant of Bifidobacterium breve induces dendritic cell maturation, activation, and survival through a Toll-like receptor 2 pathway [J].
Hoarau, C ;
Lagaraine, C ;
Martin, L ;
Velge-Roussel, F ;
Lebranchu, Y .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (03) :696-702
[12]   Resistance to simulated gastrointestinal conditions and adhesion to mucus as probiotic criteria for Bifidobacterium longum strains [J].
Izquierdo, E. ;
Medina, M. ;
Ennahar, S. ;
Marchioni, E. ;
Sanz, Y. .
CURRENT MICROBIOLOGY, 2008, 56 (06) :613-618
[13]   Celiac disease: pathogenesis of a model immunogenetic disease [J].
Kagnoff, Martin F. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (01) :41-49
[14]   Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults [J].
Kekkonen, Riina A. ;
Lummela, Netta ;
Karjalainen, Heli ;
Latvala, Sinikka ;
Tynkkynen, Soile ;
Jarvenpaa, Salme ;
Kautiainen, Hannu ;
Julkunen, Ilkka ;
Vapaatalo, Heikki ;
Korpela, Riitta .
WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (13) :2029-2036
[15]   Lactobacillus casei Downregulates Commensals' Inflammatory Signals in Crohn's Disease Mucosa [J].
Llopis, Marta ;
Antolin, Maria ;
Carol, Monica ;
Borruel, Natalia ;
Casellas, Francesc ;
Martinez, Cristina ;
Espin-Basany, Eloy ;
Guarner, Francisco ;
Malagelado, Juon-R. .
INFLAMMATORY BOWEL DISEASES, 2009, 15 (02) :275-283
[16]  
MACATONIA SE, 1995, J IMMUNOL, V154, P5071
[17]   Probiotics, prebiotics, synbiotics: ecological treatment for inflammatory bowel disease? [J].
Marteau, P. .
GUT, 2006, 55 (12) :1692-1693
[18]   Differential immunomodulatory properties of Bifidobacterium logum strains:: relevance to probiotic selection and clinical applications [J].
Medina, M. ;
Izquierdo, E. ;
Ennahar, S. ;
Sanz, Y. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (03) :531-538
[19]   Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients [J].
Medina, Marcela ;
De Palma, Giada ;
Ribes-Koninckx, Carmen ;
Calabuig, Miguel ;
Sanz, Yolanda .
JOURNAL OF INFLAMMATION-LONDON, 2008, 5 (1)
[20]  
Meyaard L, 1996, J IMMUNOL, V156, P2776